Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase NA 1Phase 3 1Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 149Gastrointestinal 31Gynecologic 26Breast 26Genitourinary 25Head & Neck 23Dermatologic 15Endocrine 13Sarcoma 9Other solid neoplasm 6NET 5Lymphoid 3CNS 3Plasma cell 2Other hematologic neoplasm 2Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 212Leukemia, Myeloid, Acute 178Leukemia 89Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Leukemia, Myelogenous, Chronic, BCR-ABL Positive 81Myeloproliferative Disorders 62Leukemia, Myelomonocytic, Chronic 61Lymphoma, Non-Hodgkin 48Multiple Myeloma 43Primary Myelofibrosis 41Hodgkin Disease 37Lymphoma 36Blast Crisis 32Leukemia, Lymphocytic, Chronic, B-Cell 29Hematologic Neoplasms 29Polycythemia Vera 26Leukemia, Myeloid, Chronic-Phase 26Leukemia, Myeloid, Accelerated Phase 26Lymphoma, Mantle-Cell 24Thrombocythemia, Essential 23Lymphoma, Follicular 21Lymphoma, Large B-Cell, Diffuse 20Burkitt Lymphoma 20Anemia, Refractory, with Excess of Blasts 20Myelodysplastic-Myeloproliferative Diseases 19Recurrence 18Congenital Abnormalities 18Neoplasms, Plasma Cell 16Lymphoma, B-Cell, Marginal Zone 16Lymphoma, Large-Cell, Immunoblastic 15

Interventions

Tretinoin 1Nivolumab 1INCB059872 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Small Cell Lung Carcinoma × Myeloid × Clear all
NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
116 enrolled 36 charts
MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡